The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma

被引:4
作者
Barbour, Andrew B. [1 ]
Kirste, Simon [2 ]
Grosu, Anca-Liga [2 ]
Siva, Shankar [3 ]
Louie, Alexander V. [4 ]
Onishi, Hiroshi [5 ]
Swaminath, Anand [6 ]
Teh, Bin S. [7 ]
Psutka, Sarah P. [8 ]
Weg, Emily S. [1 ]
Chen, Jonathan J. J. [1 ]
Zeng, Jing [1 ]
Gore, John L. [8 ]
Hall, Evan [9 ]
Liao, Jay J. J. [1 ]
Correa, Rohann J. M. [10 ]
Lo, Simon S. [1 ]
机构
[1] Univ Washington, Fred Hutchinson Canc Ctr, Dept Radiat Oncol, Seattle, WA 98195 USA
[2] Univ Freiburg, Partner Site Freiburg, German Canc Consortium DKTK, Dept Radiat Oncol,Med Ctr,Fac Med, D-79085 Freiburg, Germany
[3] Univ Melbourne, Peter MacCallum Canc Ctr, Div Radiat Oncol & Canc Imaging, Parkville, Vic 3052, Australia
[4] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Toronto, ON M5S 1A1, Canada
[5] Univ Yamanashi, Sch Med, Dept Radiol, Yamanashi 4093898, Japan
[6] McMaster Univ, Juravinski Canc Ctr, Div Radiat Oncol, Hamilton, ON L8V 5C2, Canada
[7] Houston Methodist Hosp, Canc Ctr & Res Inst, Dept Radiat Oncol, Houston, TX 77030 USA
[8] Univ Washington, Fred Hutchinson Canc Ctr, Dept Urol, Seattle, WA 98195 USA
[9] Univ Washington, Fred Hutchinson Canc Ctr, Dept Med Oncol, Seattle, WA 98195 USA
[10] London Hlth Sci Ctr, Dept Radiat Oncol, London, ON N6A 5W9, Canada
关键词
kidney cancer; radiation oncology; RCC; renal cancer; renal carcinoma; SABR; SBRT; stereotactic body radiation therapy; BODY RADIATION-THERAPY; RADIOSURGERY ONCOLOGY CONSORTIUM; POOR SURGICAL CANDIDATES; DOSE-ESCALATION; KIDNEY CANCER; RADIOFREQUENCY ABLATION; TUMOR ABLATION; MASSES; METAANALYSIS; TOXICITY;
D O I
10.3390/cancers15143672
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Patients with localized renal cell carcinoma often have medical comorbidities limiting their surgical candidacy, thus necessitating less invasive treatment options. Stereotactic ablative radiotherapy has emerged as a safe and effective management option with a growing body of evidence supporting its use. This article discusses recent advances in the use of stereotactic ablation radiotherapy for localized renal cell carcinoma, while guiding providers on practical points for patient selection and clinical application. Localized renal cell carcinoma is primarily managed surgically, but this disease commonly presents in highly comorbid patients who are poor operative candidates. Less invasive techniques, such as cryoablation and radiofrequency ablation, are effective, but require percutaneous or laparoscopic access, while generally being limited to cT1a tumors without proximity to the renal pelvis or ureter. Active surveillance is another management option for small renal masses, but many patients desire treatment or are poor candidates for active surveillance. For poor surgical candidates, a growing body of evidence supports stereotactic ablative radiotherapy (SABR) as a safe and effective non-invasive treatment modality. For example, a recent multi-institution individual patient data meta-analysis of 190 patients managed with SABR estimated a 5.5% five-year cumulative incidence of local failure with one patient experiencing grade 4 toxicity, and no other grade & GE;3 toxic events. Here, we discuss the recent developments in SABR for the management of localized renal cell carcinoma, highlighting key concepts of appropriate patient selection, treatment design, treatment delivery, and response assessment.
引用
收藏
页数:13
相关论文
共 79 条
  • [1] Outcomes of Radiofrequency Ablation for Solitary T1a Renal Cell Carcinoma: A 20-Year Tertiary Cancer Center Experience
    Abdelsalam, Mohamed E.
    Awad, Ahmed
    Baiomy, Ali
    Irwin, David
    Karam, Jose A.
    Matin, Surena F.
    Sheth, Rahul A.
    Habibollahi, Peiman
    Odisio, Bruno C.
    Lu, Thomas
    Ahrar, Kamran
    [J]. CANCERS, 2023, 15 (03)
  • [2] Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective
    Abou Elkassem, Asser M.
    Lo, Simon S.
    Gunn, Andrew J.
    Shuch, Brian M.
    Dewitt-Foy, Molly E.
    Abouassaly, Robert
    Vaidya, Sandeep S.
    Clark, Joseph, I
    Louie, Alexander, V
    Siva, Shankar
    Grosu, Anca-Ligia
    Smith, Andrew D.
    [J]. RADIOGRAPHICS, 2021, 41 (05) : 1387 - 1407
  • [3] Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel
    Abu-Ghanem, Yasmin
    Fernandez-Pello, Sergio
    Bex, Axel
    Ljungberg, Borje
    Albiges, Laurence
    Dabestani, Saeed
    Giles, Rachel H.
    Hofmann, Fabian
    Hora, Milan
    Kuczyk, Markus A.
    Kuusk, Teele
    Marconi, Lorenzo
    Merseburger, Axel S.
    Tahbaz, Rana
    Staehler, Michael
    Volpe, Alessandro
    Powles, Thomas
    Lam, Thomas B.
    Bensalah, Karim
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (04): : 433 - 452
  • [4] Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies
    Bae, Sun Hyun
    Kim, Mi-Sook
    Kim, So Young
    Jang, Won Il
    Cho, Chul Koo
    Yoo, Hyung Jun
    Kim, Kum Bae
    Lee, Dong Han
    Han, Chul Ju
    Yang, Ki Young
    Kim, Sang Bum
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2013, 28 (12) : 1707 - 1713
  • [5] Stereotactic body radiation therapy: The report of AAPM Task Group 101
    Benedict, Stanley H.
    Yenice, Kamil M.
    Followill, David
    Galvin, James M.
    Hinson, William
    Kavanagh, Brian
    Keall, Paul
    Lovelock, Michael
    Meeks, Sanford
    Papiez, Lech
    Purdie, Thomas
    Sadagopan, Ramaswamy
    Schell, Michael C.
    Salter, Bill
    Schlesinger, David J.
    Shiu, Almon S.
    Solberg, Timothy
    Song, Danny Y.
    Stieber, Volker
    Timmerman, Robert
    Tome, Wolfgang A.
    Verellen, Dirk
    Wang, Lu
    Yin, Fang-Fang
    [J]. MEDICAL PHYSICS, 2010, 37 (08) : 4078 - 4101
  • [6] Campbell SC, 2021, J UROLOGY, V206, P209, DOI 10.1097/JU.0000000000001912
  • [7] Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I
    Campbell, Steven C.
    Clark, Peter E.
    Chang, Sam S.
    Karam, Jose A.
    Souter, Lesley
    Uzzo, Robert G.
    [J]. JOURNAL OF UROLOGY, 2021, 206 (02) : 199 - 208
  • [8] Epidemiology of Renal Cell Carcinoma
    Capitanio, Umberto
    Bensalah, Karim
    Bex, Axel
    Boorjian, Stephen A.
    Bray, Freddie
    Coleman, Jonathan
    Gore, John L.
    Sun, Maxine
    Wood, Christopher
    Russo, Paul
    [J]. EUROPEAN UROLOGY, 2019, 75 (01) : 74 - 84
  • [9] Role of Active Surveillance for Localized Small Renal Masses
    Carmen Mir, Maria
    Capitanio, Umberto
    Bertolo, Riccardo
    Ouzaid, Idir
    Salagierski, Maciej
    Kriegmair, Maximilian
    Volpe, Alessandro
    Jewett, Michael A. S.
    Kutikov, Alexander
    Pierorazio, Phillip M.
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2018, 1 (03): : 177 - 187
  • [10] DMSA-SPECT: A Novel Approach to Nephron Sparing SBRT for Renal Cell Carcinoma
    Chevli, Neil
    Chiang, Stephen B.
    Farach, Andrew M.
    Haque, Waqar
    Satkunasivam, Raj
    Bernicker, Eric H.
    Pino, Ramiro
    Butler, E. Brian
    Teh, Bin S.
    [J]. ADVANCES IN RADIATION ONCOLOGY, 2021, 6 (06)